Injections play a crucial role in the treatment of macular degeneration, particularly in the management of wet age-related macular degeneration (AMD).

Q: What is Macular Degeneration?

Macular degeneration is a leading cause of vision loss among people aged 50 and older. It affects the macula, the part of the eye responsible for sharp, central vision.

Q: What types of Macular Degeneration exist?

• Wet Age-Related Macular Degeneration
• Dry Age-Related Macular Degeneration

Q: How do injections work in treating Macular Degeneration?

Injections, particularly of anti-VEGF (vascular endothelial growth factor) agents, are used to reduce the growth of abnormal blood vessels in the retina that can lead to vision loss in wet AMD.

Q: What are the most common types of injections used?

• Aflibercept (Eylea)
• Ranibizumab (Lucentis)
• Brolucizumab (Beovu)

Q: What is the therapy schedule for these injections?

Initially, patients may receive these injections monthly or bi-monthly, followed by fewer treatments as their condition stabilizes.

Key Statistics for Injection Therapy in Macular Degeneration (2023)

Q: What are the benefits of injection therapy?

• Slows down vision loss
• Can improve vision in some patients
• Minimally invasive compared to surgical options

Q: What are the potential risks or side effects of injection therapy?

• Infection at the injection site
• Retinal detachment
• Intraocular pressure increase

Cognitive Map of Injection Therapy in Macular Degeneration

1. Diagnosis of Macular Degeneration
2. Assessment of type (wet or dry)
3. Decision to treat (injection or other modalities)
4. Administration of anti-VEGF injection
5. Regular follow-ups and monitoring
6. Adjust treatment plan as necessary

Conclusion

This year, injection therapies remain a cornerstone treatment for wet macular degeneration, greatly impacting patient outcomes and maintaining vision.